Piscataqua Savings Bank Has $998,000 Stock Position in Danaher Co. (NYSE:DHR)

Piscataqua Savings Bank lessened its holdings in shares of Danaher Co. (NYSE:DHR) by 1.1% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 4,346 shares of the conglomerate’s stock after selling 50 shares during the period. Piscataqua Savings Bank’s holdings in Danaher were worth $998,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Cornerstone Wealth Group LLC boosted its stake in Danaher by 9.1% during the 4th quarter. Cornerstone Wealth Group LLC now owns 1,179 shares of the conglomerate’s stock worth $271,000 after acquiring an additional 98 shares during the last quarter. Union Bancaire Privee UBP SA acquired a new stake in Danaher in the fourth quarter worth $74,551,000. Capital Asset Advisory Services LLC boosted its position in shares of Danaher by 4.2% during the fourth quarter. Capital Asset Advisory Services LLC now owns 10,973 shares of the conglomerate’s stock worth $2,577,000 after purchasing an additional 440 shares in the last quarter. Blue Trust Inc. grew its holdings in shares of Danaher by 75.7% in the 4th quarter. Blue Trust Inc. now owns 16,615 shares of the conglomerate’s stock valued at $3,814,000 after buying an additional 7,157 shares during the period. Finally, Jamison Private Wealth Management Inc. increased its position in shares of Danaher by 1.7% in the 4th quarter. Jamison Private Wealth Management Inc. now owns 9,756 shares of the conglomerate’s stock valued at $2,239,000 after buying an additional 159 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on DHR shares. Bank of America raised Danaher from a “neutral” rating to a “buy” rating and set a $290.00 target price for the company in a research note on Friday, December 13th. Stifel Nicolaus boosted their price objective on Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research report on Wednesday, October 23rd. Robert W. Baird dropped their target price on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Stephens reiterated an “overweight” rating and issued a $315.00 price target on shares of Danaher in a report on Wednesday, October 23rd. Finally, Guggenheim assumed coverage on shares of Danaher in a report on Thursday, December 19th. They set a “buy” rating and a $275.00 price objective on the stock. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $285.55.

Danaher Price Performance

NYSE:DHR opened at $245.95 on Monday. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. Danaher Co. has a 12-month low of $225.42 and a 12-month high of $281.70. The stock’s 50 day moving average price is $235.33 and its two-hundred day moving average price is $253.62. The firm has a market capitalization of $177.65 billion, a price-to-earnings ratio of 46.94, a P/E/G ratio of 4.43 and a beta of 0.83.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.44%. The ex-dividend date is Friday, December 27th. Danaher’s dividend payout ratio is 20.61%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.